Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure

Project description

Enhancing survival and quality of life of CO2-impaired patients

Hypercapnia refers to a dangerous build-up of CO2 in the blood. It affects millions of people, including premature babies, intensive care unit patients with lung failure and those with chronic obstructive pulmonary disease. Current treatments often fall short in treating this condition. The EIC-funded RESPILIQ project aims to revolutionise therapy and significantly improve survival. Instead of tackling the problem via the lungs, researchers will use the human gut as a respiratory organ, leveraging its natural ability to exchange CO2. Administered orally or rectally, it binds CO2 in the intestinal fluid and safely removes it, reducing blood CO2 levels. The proposed research aims to improve survival rates and dramatically enhance the quality of life for those suffering from hypercapnia.

Objective

Premature babies and patients with acute lung failure in the intensive care unit or COPD patients at home: they all suffer from the same potentially fatal condition: hypercapnia = an increased level of CO2 in the blood. In Europe alone there are around 1.8M people. Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU and in the outpatient treatment of COPD, which has not yet been adequately solved. Our goal is to revolutionize therapy and significantly improve survival and, above all, the quality of life of these large patient groups suffering from hypercapnia. Instead of tackling the
problem via the lungs, RESPILIQ uses the human gut as a respiratory organ. The intestine forms a highly effective exchange membrane for carbon dioxide (CO2). In the gut, RESPILIQ can bind CO2 from the intestinal fluid and excrete it via naturalis. Administered orally or rectally, RESPILIQ initiates a life-saving reduction of pCO2 in the blood

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

O11 BIOMEDICAL GMBH
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 499 999,00
Address
SCHLOSSPARKSTR. 93
52072 Aachen
Germany

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 3 603 638,83
My booklet 0 0